Insights on the Indian API, Formulation and CRAMS via a recent report from o3 Capital.
Tailwinds (China+1): 10% market share switch from China can double Indian API market.
Headwinds: Rising input costs in China due to power outage + freight hike. India has high dependency.
1/n
Tailwinds (China+1): 10% market share switch from China can double Indian API market.
Headwinds: Rising input costs in China due to power outage + freight hike. India has high dependency.
1/n
2/n
Indian API landscape
Scale, capacity, DMF filings, focus segments/ therapy areas and leading products.
#Divis #LaurusLabs #Granules #AartiDrugs #Solara
Indian API landscape
Scale, capacity, DMF filings, focus segments/ therapy areas and leading products.
#Divis #LaurusLabs #Granules #AartiDrugs #Solara
3/n
Growth strategies adopted by API companies
- Diversifying beyond API and CRAMS into Formulations, Biologics and Nutraceuticals.
- Laurus: Forward integrated into drug development via contracts from NATCO, Citron, Dr. Reddy + foray into new markets + new segments (Biologics)
Growth strategies adopted by API companies
- Diversifying beyond API and CRAMS into Formulations, Biologics and Nutraceuticals.
- Laurus: Forward integrated into drug development via contracts from NATCO, Citron, Dr. Reddy + foray into new markets + new segments (Biologics)
4/n
Solara - Merger with Aurora L/S triples CRAMS revenue + customer & geographic diversification + new product (ARV)
Divis - Backward integration in key products like Naproxen (70% share) - lowest-cost producer. 1200 cr Capex.
Aarti Drugs - Forward integrated into Formulations
Solara - Merger with Aurora L/S triples CRAMS revenue + customer & geographic diversification + new product (ARV)
Divis - Backward integration in key products like Naproxen (70% share) - lowest-cost producer. 1200 cr Capex.
Aarti Drugs - Forward integrated into Formulations
5/n
Understanding the scale and margin profile of key API companies.
Understanding the scale and margin profile of key API companies.
6/n
Segment snapshot: CRAMS players command higher EBITDA margins than pure API companies (28% vs 15%) and thus higher valuations.
Segment snapshot: CRAMS players command higher EBITDA margins than pure API companies (28% vs 15%) and thus higher valuations.
7/n
Valuation multiples metrics of all companies in API, Formulations and CRAMS
Valuation multiples metrics of all companies in API, Formulations and CRAMS
Join the Multipie community for more curated insights and feautures.
multipie.co
multipie.co
Loading suggestions...